Disc Medicine, Inc. annual report, FY2021

Filing summary

Entity and period: The supplied filing is Gemini Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 10, 2022; it identifies the company as Gemini Therapeutics and its Nasdaq ticker as GMTX. This does not match the request metadata naming Disc Medicine, Inc. Investors should verify the issuer before relying on this summary. The financial results below cover the full year, not Q4 alone.

Business context and reporting period

Gemini was a clinical-stage precision-medicine company developing therapies for genetically defined age-related macular degeneration (AMD). Its lead candidate, GEM103, is recombinant human complement factor H. GEM307, a preclinical factor H-potentiating antibody program, was also disclosed. The company had no approved products and no product-sales revenue.

Financial performance and position

Operating expenses rose by $35.0 million year over year, mainly from higher GEM103 clinical-development costs, personnel and stock-based compensation, and public-company legal, insurance and professional fees. Net loss increased by $31.0 million. The lower loss per share in 2021 reflects a higher weighted-average share count following the business combination; it does not indicate improved profitability. Gross margin and operating margin are not meaningful for a company without product revenue.

Financing activities provided $191.5 million in 2021, primarily from $195.9 million of net proceeds from the February 2021 business combination and PIPE financing, partly offset by term-loan principal payments. Investing activities provided $0.3 million, primarily from asset-sale proceeds. Year-end current assets were $140.1 million and current liabilities were $14.8 million; the resulting current ratio is approximately 9.4x, calculated from the reported balances. The company reported $5.4 million of term-loan principal outstanding, including $5.0 million current and $0.4 million long-term net of discount. Convertible notes had converted before the business combination and no balance remained at year-end. Accumulated deficit was $184.7 million.

Material changes and developments

• Both GEM103 Phase 2a trials—the ReGAtta dry-AMD study and the wet-AMD add-on study—were discontinued in January 2022 after management said they had served their intended safety-and-tolerability purpose. The filing reports preliminary tolerability and biomarker observations but no pivotal efficacy evidence or completed pivotal trials.
• In October 2021, Gemini reduced its workforce by 11 positions, approximately 26%, and recorded $1.4 million in restructuring costs.
• On February 28, 2022, the company announced a further reduction of up to 24 positions, approximately 80% of the workforce, expected by the end of Q2 2022. Estimated costs were $1.6 million to $1.9 million.
• Gemini initiated a strategic-alternatives review, with no timetable or definitive course of action announced. The board said there was no assurance of a transaction or additional cash distributions to stockholders.
• On February 28, 2022, Georges Gemayel became interim President and CEO, succeeding Jason Meyenburg, who remained an advisor. The company also moved to a remote-first arrangement and had no physical properties after terminating its Cambridge lease at year-end 2021.

Outlook, risks and unusual items

Management expected 2022 R&D and G&A expenses to decline because of reduced clinical activity and restructuring. It stated that year-end cash was expected to fund operating expenses and capital requirements for at least twelve months from the filing date, subject to strategic alternatives and assumptions that could prove incorrect. No product-revenue, earnings or clinical-development guidance was provided.

Key risks include failure to complete a strategic transaction, continued cash burn, possible liquidation and uncertain distributions after reserves for obligations, workforce and management attrition, and the absence of ongoing clinical trials following GEM103 discontinuation. GEM307 remained preclinical. The company also cited dependence on third-party manufacturers and research organizations, regulatory and clinical-development uncertainty, competition, intellectual-property risks, and potential dilution or financing constraints. The filing notes that Gemini’s market capitalization was below the value of its cash and cash equivalents, while also warning that a counterparty might assign little or no value to its programs.

Unusual reported items included $7.8 million of stock-based compensation in 2021, a $0.7 million loss on conversion of convertible notes, and $1.4 million of 2021 restructuring costs. The financial statements received an unqualified audit opinion. Management assessed disclosure controls and internal control over financial reporting as effective at December 31, 2021; the auditor did not provide an internal-control attestation.

Important facts for investors to verify

• Confirm the issuer: the filing is for Gemini Therapeutics, Inc. (GMTX), not Disc Medicine, Inc.
• Review subsequent filings for the outcome and costs of the strategic review, restructuring, and any liquidation or transaction decision.
• Verify actual cash burn, obligations, and runway after restructuring and strategic-review expenses; the stated runway is management’s estimate.
• Review final results and disclosures from the discontinued GEM103 studies, distinguishing preliminary safety and biomarker findings from evidence of clinical efficacy.
• Assess the status and funding requirements of GEM307 and any rights, licensing obligations, or future development plans.
• Check current share count, equity awards, registration rights and potential dilution; the filing reported 43,208,159 shares outstanding as of February 28, 2022.